Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403639 | 0.74 | CA2 (0.43) | CA1ESR1ESR2TRPA1CA2 | |
| SCHEMBL20469912 | 0.72 | CA1 (0.59) | CA1TRPA1MGLLTUBB1TP53 | |
| SCHEMBL862053 | 0.71 | CA2 (0.52) | CA1ESR1ESR2CA2TP53 | |
| SCHEMBL29790333 | 0.71 | CA2 (0.52) | CA1ESR1ESR2CA2TP53 | |
| SCHEMBL8469357 | 0.71 | CA2 (0.52) | CA1ESR1ESR2CA2TP53 | |
| SCHEMBL28204119 | 0.71 | TRPA1 (0.48) | CA1ESR1ESR2TRPA1TUBB1 | |
| Catechol SCHEMBL9641287 | 0.69 | CA2 (0.50) | CA1ESR1ESR2CA2TP53 | |
| SCHEMBL337282 | 0.69 | CA2 (0.50) | CA1ESR1ESR2CA2TP53 | |
| Ammonia Solution, Strong SCHEMBL9187024 | 0.69 | CA2 (0.50) | CA1ESR1ESR2CA2TP53 | |
| SCHEMBL3228199 | 0.68 | CA2 (0.45) | CA1ESR1ESR2CA2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652035-B2 | CRF receptor antagonists and methods relating thereto | Neurocrine Bioscience, Inc. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1802621-B1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SMITHKLINE BEECHAM CORK LTD (IE) | 2009-05-06 | — | — | EP | disclosed |
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2008-03-13 | — | — | US | disclosed |
| EP-1802621-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB Pharmco Puerto Rico Inc. (PR) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006044821-A1 | CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | SB PHARMCO PUERTO RICO INC. (PR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064719-A1 | Crf Receptor Antagonists And Methods Relating Thereto | CRHR1, CRHR2, SCTR | CA1 1240/4885ESR1 323/4885ESR2 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.